Diagnostic Utility of 18F-FDG PECT/CT in Assessment of Post-therapy Remission or Relapse of Lymphoma

Nagham Nabil Omar¹, Mostafa Shaker Abolela², Marwa I. Abdelgawad^3, , Abeer Ibrahim⁴, Amr F. Mourad⁵ and Khalid Rezk⁶

¹Radiology Department, Assuit University, Egypt

²Radiology Department, Nasser Institute Hospital

³Clinical Oncology Department, Assiut University, Egypt

⁴Medical Oncology Department, South Egypt Cancer Inistitute

⁵Radiodiagnosis Department, South Egypt Cancer Inistitute

⁶Surgical Oncology Department, South Egypt Cancer Inistitute

Cite this paper:
Nagham Nabil Omar, Mostafa Shaker Abolela, Marwa I. Abdelgawad, Abeer Ibrahim, Amr F. Mourad and Khalid Rezk. Diagnostic Utility of 18F-FDG PECT/CT in Assessment of Post-therapy Remission or Relapse of Lymphoma. Journal of Cancer Research and Treatment. 2016; 4(5):88-95. doi: 10.12691/jcrt-4-5-3

Abstract

Background: Treatment and prognosis of lymphoma depend on accurate staging and evaluation. Relapsed Lymphomas represent great problem in accurate quick diagnosis that imply appropriate treatment. Aim of the work: To evaluate diagnostic utility of 18F-FDG PECT/CT in assessment of treatment response and identification of disease relapse. Patients and Methods: This prospective study were conducted on 49 consecutive patients with histologically verified lymphoma. They were 27/49 (55.1%) male and 22/49 (44.9%) female aged 37.83±2.29. All patients were subjected to pretreatment as well a follow up clinical, laboratory, CT PET-CT. PET-CT findings were classified as positive and negative according to remission status and relapse. The sensitivity, specificity and accuracy of PET- CT in assessment of the remission status and relapse were calculated and to be confirmed by open or laparoscopic biopsy. Results: PET-CT detected complete regression in 28 patients (57.14%), partial regression in 4 patients (8.16%), stationary course in 2 patients (4.08%), progression / relapse in 15 patients (30.61%). According to PET/CT 9 (23%) patients were true positive, 25 (65%) were true negative and 5 (13%) were false negative with sensitivity, specificity, positive p predictive value and negative predictive value of 95% and 91%, 90% and 98%, respectively. Conclusion: Our results confirm FDG-PET as a valid tool for assessment of treatment response and detection of relapsing lymphoma. We recommended further multicentric prospective studies that incorporates a larger number of patients should be implemented to define the exact relation between certain clinical, pathological, laboratory and PET factors and fate of the disease.

Keywords:
18F-FDG PECT/CT lymphoma CT Treatment Relapsed Lymphoma

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Younes A: Early-stage Hodgkin’s lymphoma: In pursuit of perfection. J Clin Oncol 30: 895-896, 2012.
[2]	Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002.
[3]	Cheson BD: Role of functional imaging in the management of lymphoma. J Clin Oncol 29: 1844-1854, 2011.
[4]	Hutchings M, Loft A, Hansen M, et al: Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91: 482-489, 2006.
[5]	Rigacci L, Vitolo U, Nassi L, et al: Positronemission tomography in the staging of patients with Hodgkin’s lymphoma: A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 86: 897-903, 2007.
[6]	Raanani P, Shasha Y, Perry C, et al: Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 17: 117-122, 2006
[7]	Elstrom R, Leonard JP, Coleman M, et al: Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 19: 1770-1773, 2008
[8]	Pelosi E, Pregno P, Penna D, et al: Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDGPET/ CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma [in English, Italian]. Radiol Med 113: 578-590, 2008
[9]	Karam M, Novak L, Cyriac J, et al: Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107: 175-183, 2006
[10]	Janikova A, Bolcak K, Pavlik T, et al: Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma? Clin Lymphoma Myeloma 8: 287-293, 2008.
[11]	Wirth A, Foo M, Seymour JF, et al: Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys 71:213-219, 2008.
[12]	Le Dortz L, De Guibert S, Bayat S, et al: Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med MolImaging 37: 2307-2314, 2013.
[13]	Juweid ME, Stroobants S, Hoekstra OS, etal: Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25: 571-578, 2007.
[14]	Casasnovas RO ,Meignan M, Riedinger A, etal: SUV max reduction improves early Prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118: 37-43, 2011.
[15]	Christian F, Ingo G. S, Holger A, Juri R, Daniel M, et al: Early and Late Therapy Response Assessment With [18F] Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial.
[16]	Lavely WC, Delbeke D,Creer JP, et al: FDC PET in the follow up management of patients with newly diagnosed Hodgkin and non-Hodgkin Iymphoma after first line chemotherapy. Int J Radiat Oncol Biol Phys 57:307-315, 2003.
[17]	Zinzani PL, Vittorio S, Monica T, Stefano F, Gerardo M, et al . Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma. J Clin Oncol 2009; 27:1781-1787.
[18]	Lin C, Itti E, Haioun C, et al: Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48: 1626-2014.
[19]	Wahl RL, Jacene H, Kasamon Y, etal: From RECIST to PERCIST: Evolving considerations for PET response criteriain solid tumors. J Nucl Med 139.
[20]	Boellaar dR: Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med 52:93S-100S, 2011.
[21]	Kostakoglu L,Scho¨derH, Johnson JL, etal: Interim [(18)F] fluorodeoxy glucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: Would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma53: 2143-2150, 2012.
[22]	Sally F. B , George M., Lale K, Michel M, Martin H, et al : Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. JCO. 2013. 53: 5229-5236. JCO 2009; 27: 4385-4391.
[23]	Yang DH, Ahn JS, Byun BH, etal: Interim PET/CT-based prognostic model for the treatment of diffuse large B- cell lymphoma in the postrituximabera. AnnHemato l92: 471-479, 2013.
[24]	Fuertes S, Setoain X, Lopez-Guillermo A, et al: Interim FDGPET/CT as a prognosticf actor in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 40: 496-504, 2013.
[25]	Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology. 2003; 64(4): 336-40.
[26]	Bishu S, Quigley JM, Schmitz J, Bishu SR, Stemm RA, Olsasky SM, et al. F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma. 2007 Aug; 48(8): 1531-8.
[27]	Wu LM, Chen FY, Jiang XX, Gu HY, Yin Y, Xu JR. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis. Eur J Radiol. 2012 Feb; 81(2): 303-11.
[28]	Martin R. Weihrauch, Daniel Re, Klemens Scheidhauer, Sascha Anse´ n, Markus Dietlein, Stefanie Bischoff, Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001; 98: 2930-2934.
[29]	Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F- fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999 Jul 15; 94(2): 429-33.
[30]	Rhodes MM, Delbeke D, Whitlock JA, et al: Utility of FDG-PET/CT in follow-up of children treatedfor Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 28: 300-306, 2006.
[31]	Zinzani PL, Musuraca G, Alinari L, etal: Pre dictiverole of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 7: 291-295, 2007.